HUNTSVILLE, Ala., April 18, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development based upon poly(oxazoline) - POZ, announced today that the company has entered into a definitive agreement with Woodside Capital Partners retaining them as the Company's advisor and investment bank. The details of the agreement were not disclosed.
"We are very pleased to announce that Serina Therapeutics has reached an agreement to have Woodside Capital Partners serve as our advisor and investment bank. Woodside Capital and its elite group of partners and life science advisors have a remarkable track record of helping to create shareholder value in promising biotechnology companies," said Randall Moreadith, MD, PhD, President and Chief Executive Officer of Serina. "Now that we are beginning to move our first clinical candidate toward Phase I in early 2014, and have signed an alliance with a large pharmaceutical partner for development of a POZ-therapeutic, we felt it was time to bring in an expert in doing deals across a wide range of companies in the pharmaceutical industry. We think Woodside Partners fills that need exceptionally well."
"Woodside Capital looks forward to working with the seasoned management team and board at Serina to complete additional transactions with selected pharmaceutical partners," said John Selig, Managing Director and co-head of Woodside Capital's Life Sciences Group. "We believe Serina's POZ technology has the potential to significantly improve the product profile of a large number of molecules across therapeutic areas."
Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary poly(oxazoline) (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.
For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com
About Woodside Capital Partners
Woodside Capital Partners is a global investment bank with offices in Silicon Valley and London that delivers world-class strategic and financial advice to emerging growth companies in the life sciences and technology sectors. With a strong track record in strategic partnerships, M&A and private placements, Woodside Capital has been providing investment banking services worldwide since 2001 with leading domain experience in life sciences, software, Internet services, electronic communications and materials. The team of Woodside Capital has completed transactions totaling more than $10 billion. The firm is also the Silicon Valley headquarters of M&A International, the world's leading mergers and acquisitions alliance.
For more information on Woodside Capital, please visit www.woodsidecap.com.
SOURCE Serina Therapeutics, Inc.